Tsimafeyeu I - Search Results

1

FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.

Tsimafeyeu I, Khasanova A, Stepanova E, Gordiev M, Khochenkov D, Naumova A, Varlamov I, Snegovoy A, Demidov L. Tsimafeyeu I, et al. Clin Transl Oncol. 2017 Feb;19(2):265-268. doi: 10.1007/s12094-016-1524-y. Epub 2016 Jul 5. Clin Transl Oncol. 2017. PMID: 27379982

2

Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma.

Tsimafeyeu IV, Demidov LV, Madzhuga AV, Somonova OV, Yelizarova AL. Tsimafeyeu IV, et al. J Exp Clin Cancer Res. 2009 Mar 2;28(1):30. doi: 10.1186/1756-9966-28-30. J Exp Clin Cancer Res. 2009. PMID: 19254383 Free PMC article.

3

Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.

Tsimafeyeu I, Demidov L, Stepanova E, Wynn N, Ta H. Tsimafeyeu I, et al. Scand J Urol Nephrol. 2011 Apr;45(3):190-5. doi: 10.3109/00365599.2011.552436. Epub 2011 Feb 18. Scand J Urol Nephrol. 2011. PMID: 21329481

4

Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.

Tsimafeyeu I, Demidov L. Tsimafeyeu I, et al. J Cancer Res Ther. 2010 Oct-Dec;6(4):575-7. doi: 10.4103/0973-1482.77084. J Cancer Res Ther. 2010. PMID: 21358107 Free article.

5

Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.

Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Galchenko V, Sinelnikov I, Naidzionak U. Tsimafeyeu I, et al. Am J Clin Oncol. 2012 Jun;35(3):251-4. doi: 10.1097/COC.0b013e31820dbc17. Am J Clin Oncol. 2012. PMID: 21358295 Clinical Trial.

6

Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.

Tsimafeyeu I, Zart JS, Chung B. Tsimafeyeu I, et al. BJU Int. 2013 Jul;112(1):32-8. doi: 10.1111/bju.12107. Epub 2013 Jun 7. BJU Int. 2013. PMID: 23746142 Clinical Trial.

7

OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model.

Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. Tsimafeyeu I, et al. Invest New Drugs. 2013 Dec;31(6):1436-43. doi: 10.1007/s10637-013-0017-x. Epub 2013 Sep 13. Invest New Drugs. 2013. PMID: 24026432

8

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.

Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, Manzuk L. Tsimafeyeu I, et al. Target Oncol. 2015 Sep;10(3):423-7. doi: 10.1007/s11523-014-0347-4. Epub 2014 Dec 4. Target Oncol. 2015. PMID: 25466382 Clinical Trial.

9

Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.

Tsimafeyeu I, Bratslavsky G. Tsimafeyeu I, et al. Oncology. 2015;88(6):321-31. doi: 10.1159/000370118. Epub 2015 Feb 7. Oncology. 2015. PMID: 25678187 Review.

10

Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.

Tsimafeyeu I. Tsimafeyeu I. J Cancer Res Ther. 2015 Oct-Dec;11(4):920-2. doi: 10.4103/0973-1482.162120. J Cancer Res Ther. 2015. PMID: 26881543 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters